← Back to Search

Histone Deacetylase Inhibitor; Tyrosine Kinase Inhibitor

Escalating doses of imatinib and LBH589 for Chordoma

Phase 1
Waitlist Available
Led By Deric M Park, MD
Research Sponsored by Deric M Park MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at time of study drug discontinuation
Awards & highlights

Study Summary

This is a multi-center study to assess the safety and to determine the maximum tolerated dose of the combination of imatinib and LBH589 in patients with newly diagnosed and recurrent chordoma. For the recurrent population, those patients that do not require immediate surgical resection will be eligible. Patients will be treated with 4 cycles, followed by surgical resection if possible. If indicated, surgery may take place prior to the completion of 4 cycles.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of dose limiting toxicities
Secondary outcome measures
Tumor response

Trial Design

1Treatment groups
Experimental Treatment
Group I: Escalating doses of imatinib and LBH589Experimental Treatment1 Intervention
Study will incorporate a "3+3" dose escalation design.

Find a Location

Who is running the clinical trial?

Deric M Park MDLead Sponsor
Deric M Park, MDPrincipal InvestigatorUniversity of Virginia
~3 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top